Mirum Pharmaceuticals (MIRM) Retained Earnings (2018 - 2026)

Mirum Pharmaceuticals' Retained Earnings history runs 9 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 581295.35% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 581295.35% YoY), while the FY2025 annual figure was -$667.5 million, down 3.63% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.5 billion, down from -$667.5 million in the prior quarter.
• The five-year high for Retained Earnings was $920000.0 in Q3 2024, with the low at -$1.5 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$423.0 million (2023), against an average of -$403.2 million.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings slumped 1122254.29% in 2022, then soared 163.1% in 2024.
• Mirum Pharmaceuticals' Retained Earnings stood at -$392.8 million in 2022, then tumbled by 41.6% to -$556.2 million in 2023, then slipped by 15.81% to -$644.2 million in 2024, then decreased by 3.63% to -$667.5 million in 2025, then plunged by 124.7% to -$1.5 billion in 2026.
• Business Quant data shows MIRM's Retained Earnings at -$1.5 billion in Q1 2026, -$667.5 million in Q4 2025, and $37000.0 in Q3 2025.